Neurol. praxi. 2011;12(4):265-269

Multiple sclerosis - current diagnostics, prognosis and treatment efficacy monitoring

MUDr.Dana Horáková, Ph.D.
Neurologická klinika a Centrum klinických neurověd, Univerzita Karlova v Praze, 1. lékařská fakulta

Multiple sclerosis is an inflammatory disease of the central nervous system that, without treatment, causes significant disability in most

patients. At present, the only prevention is early antiinflammatory treatment. Unfortunately, currently used drugs are only partially effective,

and, in most patients clinical activity persists. Accurately assessing the treatment response to disease-modifying agents enables

non-responder patients to be identified at an early stage of therapy. Patients can then be switched to another, potentially more effective



treatment: The follow up must be comprehensive and involve clinical and modern paraclinical examinations with objective evaluation

of underlying pathological processes in the central nervous system.

Keywords: multiple sclerosis, prognostic markers, early treatment, magnetic resonance imaging

Published: July 29, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horáková D. Multiple sclerosis - current diagnostics, prognosis and treatment efficacy monitoring. Neurol. praxi. 2011;12(4):265-269.
Download citation

References

  1. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002; 15: 239-245. Go to original source... Go to PubMed...
  2. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256-266. Go to original source... Go to PubMed...
  3. Bergamaschi R. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision. Expert Rev Neurother 2006; 6: 357-364. Go to original source... Go to PubMed...
  4. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999; 5: 244-250. Go to original source... Go to PubMed...
  5. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817. Go to original source... Go to PubMed...
  6. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology 2010; 74(Suppl 3): S3-7. Go to original source... Go to PubMed...
  7. Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L, Khoury S, Hartzmann R, Fernandez-Vina M, Hafler DA, Weiner HL, Guttmann CR, De Jager PL. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology 2010; 75: 634-640. Go to original source... Go to PubMed...
  8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452. Go to original source... Go to PubMed...
  9. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127. Go to original source... Go to PubMed...
  10. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC,Polman CH. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14: 1157-1174. Go to original source... Go to PubMed...
  11. Montalban X, Tintore M, Swanton J, Barkhof F, Fazekas F, Filippi M, Frederiksen J, Kappos L, Palace J, Polman C, Rovaris M, de Stefano N, Thompson A, Yousry T, Rovira A, Miller DH. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010; 74: 427-434. Go to original source... Go to PubMed...
  12. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9: 516-526. Go to original source... Go to PubMed...
  13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302. Go to original source... Go to PubMed...
  14. Ramagopalan SV, Ebers GC. Genes for multiple sclerosis. Lancet 2008; 371: 283-285. Go to original source... Go to PubMed...
  15. Rio J, Castillo J, Rovira A, Tintore M, Sastre-Garriga J, Horga A, Nos C, Comabella M, Aymerich X, Montalban X. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009a; 15: 848-853. Go to original source... Go to PubMed...
  16. Rio J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009b; 5: 553-560. Go to original source... Go to PubMed...
  17. Vaneckova MS Z, Krásenský J, Horáková D, Havrdová E, Němcová J, Daneš. Naše zkušenosti s MR monitorováním pacientů s roztroušenou sklerózou v klinické praxi. Cesk Slov Neurol N 2010; 73/106: 716-720.
  18. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003; 206: 135-137. Go to original source... Go to PubMed...
  19. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65: 239-248. Go to original source... Go to PubMed...
  20. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994; 36(Suppl): S6-11. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.